Manufacturer of Controlled Substances Registration: Patheon Pharmaceuticals, Inc., 50950 [2014-20198]
Download as PDF
<![CDATA[
50950
Federal Register / Vol. 79, No. 165 / Tuesday, August 26, 2014 / Notices
Controlled substance
Schedule
Dextropropoxyphene, bulk (nondosage forms) (9273).
Morphine (9300) ...........................
Thebaine (9333) ...........................
Levo-alphacetylmethadol (9648) ..
Oxymorphone (9652) ...................
Noroxymorphone (9668) ..............
Racemethorphan (9732) ..............
Alfentanil (9737) ...........................
Remifentanil (9739) ......................
Sufentanil (9740) ..........................
Carfentanil (9743) .........................
Tapentadol (9780) ........................
Fentanyl (9801) ............................
II
II
II
II
II
II
II
II
II
II
II
II
II
The company plans to manufacture
small quantities of the listed controlled
substances to make reference standards
which will be distributed to their
customers.
Dated: August 19, 2014.
Joseph T. Rannazzisi,
Deputy Assistant Administrator.
[FR Doc. 2014–20201 Filed 8–25–14; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
[Docket No. DEA–392]
Manufacturer of Controlled
Substances Registration: PCASNanosyn, LLC
PCAS-Nanosyn, LLC applied
to be registered as a manufacturer of
certain basic classes of narcotic and
non-narcotic controlled substances. The
DEA grants PCAS-Nanosyn, LLC
registration as a manufacturer of those
controlled substances.
SUPPLEMENTARY INFORMATION: By notice
dated April 21, 2014, and published in
the Federal Register on April 30, 2014,
79 FR 24452, PCAS-Nanosyn, LLC,
3331–B Industrial Drive, Santa Rosa,
California 95403, applied to be
registered as a manufacturer of certain
basic classes of narcotic or non-narcotic
controlled substances. No comments or
objections have been received.
The Drug Enforcement
Administration (DEA) has considered
the factors in 21 U.S.C. 823(a) and
determined that the registration of
PCAS-Nanosyn, LLC to manufacture the
basic classes of controlled substances is
consistent with the public interest and
with United States obligations under
international treaties, conventions, or
protocols in effect on May 1, 1971. The
DEA investigated the company’s
maintenance of effective controls
against diversion by inspecting and
tkelley on DSK3SPTVN1PROD with NOTICES
VerDate Mar<15>2010
21:48 Aug 25, 2014
Jkt 232001
Amphetamine (1100) ....................
Methamphetamine (1105) ............
Methylphenidate (1724) ................
Phencyclidine (7471) ....................
Codeine (9050) .............................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Hydrocodone (9193) .....................
Methadone (9250) ........................
Morphine (9300) ...........................
Oripavine (9330) ...........................
Oxymorphone (9652) ...................
Fentanyl (9801) ............................
Schedule
II
II
II
II
II
II
II
II
II
II
II
II
II
comments or objections have been
received.
The Drug Enforcement
Administration (DEA) has considered
the factors in 21 U.S.C. 823(a) and
determined that the registration of
Patheon Pharmaceuticals, Inc., to
manufacture the basic class of this
controlled substance is consistent with
the public interest and with United
States obligations under international
treaties, conventions, or protocols in
effect on May 1, 1971. The DEA
investigated the company’s maintenance
of effective controls against diversion by
inspecting and testing the company’s
physical security systems, verifying the
company’s compliance with state and
local laws, and reviewing the company’s
background and history.
Therefore, pursuant to 21 U.S.C.
823(a), and in accordance with 21 CFR
1301.33, the above-named company is
granted registration as a bulk
manufacturer of Gamma Hydroxybutyric
Acid (2010), a basic class of controlled
substance listed in schedule I.
The company plans to manufacture
the listed controlled substance for
distribution to its customers.
Dated: August 19, 2014.
Joseph T. Rannazzisi,
Deputy Assistant Administrator.
[FR Doc. 2014–20198 Filed 8–25–14; 8:45 am]
Dated: August 19, 2014.
Joseph T. Rannazzisi,
Deputy Assistant Administrator.
Notice of registration.
SUMMARY:
Controlled substance
The company is a contract
manufacturer. At the request of the
company’s customers, it manufactures
derivatives of controlled substances
only in bulk form.
Drug Enforcement Administration
ACTION:
testing the company’s physical security
systems, verifying the company’s
compliance with state and local laws,
and reviewing the company’s
background and history.
Therefore, pursuant to 21 U.S.C.
823(a), and in accordance with 21 CFR
1301.33, the above-named company is
granted registration as a bulk
manufacturer of the basic classes of
narcotic and non-narcotic controlled
substances listed:
BILLING CODE 4410–09–P
[FR Doc. 2014–20196 Filed 8–25–14; 8:45 am]
DEPARTMENT OF LABOR
BILLING CODE 4410–09–P
Office of the Secretary
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–392]
Manufacturer of Controlled
Substances Registration: Patheon
Pharmaceuticals, Inc.
ACTION:
Notice of registration.
Patheon Pharmaceuticals,
Inc., applied to be registered as a
manufacturer of a certain basic class of
controlled substance. The DEA grants
Patheon Pharmaceuticals, Inc.,
registration as a manufacturer of the
controlled substance.
SUPPLEMENTARY INFORMATION: By notice
dated April 21, 2014, and published in
the Federal Register on April 28, 2014,
79 FR 23373, Patheon Pharmaceuticals,
Inc., 2110 E. Galbraith Road, Cincinnati,
Ohio 45237, applied to be registered as
a manufacturer of a certain basic class
of non-narcotic controlled substance. No
SUMMARY:
PO 00000
Frm 00067
Fmt 4703
Sfmt 4703
Agency Information Collection
Activities; Submission for OMB
Review; Comment Request; Fire
Protection in Shipyard Employment
Standard
ACTION:
Notice.
The Department of Labor
(DOL) is submitting the Occupational
Safety and Health Administration
(OSHA) sponsored information
collection request (ICR) titled, ‘‘Fire
Protection in Shipyard Employment
Standard,’’ to the Office of Management
and Budget (OMB) for review and
approval for continued use, without
change, in accordance with the
Paperwork Reduction Act of 1995
(PRA), 44 U.S.C. 3501 et seq. Public
comments on the ICR are invited.
DATES: The OMB will consider all
written comments that agency receives
on or before September 25, 2014.
ADDRESSES: A copy of this ICR with
applicable supporting documentation;
including a description of the likely
SUMMARY:
E:\FR\FM\26AUN1.SGM
26AUN1
]]>Agencies
[Federal Register Volume 79, Number 165 (Tuesday, August 26, 2014)]
[Notices]
[Page 50950]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-20198]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-392]
Manufacturer of Controlled Substances Registration: Patheon
Pharmaceuticals, Inc.
ACTION: Notice of registration.
-----------------------------------------------------------------------
SUMMARY: Patheon Pharmaceuticals, Inc., applied to be registered as a
manufacturer of a certain basic class of controlled substance. The DEA
grants Patheon Pharmaceuticals, Inc., registration as a manufacturer of
the controlled substance.
SUPPLEMENTARY INFORMATION: By notice dated April 21, 2014, and
published in the Federal Register on April 28, 2014, 79 FR 23373,
Patheon Pharmaceuticals, Inc., 2110 E. Galbraith Road, Cincinnati, Ohio
45237, applied to be registered as a manufacturer of a certain basic
class of non-narcotic controlled substance. No comments or objections
have been received.
The Drug Enforcement Administration (DEA) has considered the
factors in 21 U.S.C. 823(a) and determined that the registration of
Patheon Pharmaceuticals, Inc., to manufacture the basic class of this
controlled substance is consistent with the public interest and with
United States obligations under international treaties, conventions, or
protocols in effect on May 1, 1971. The DEA investigated the company's
maintenance of effective controls against diversion by inspecting and
testing the company's physical security systems, verifying the
company's compliance with state and local laws, and reviewing the
company's background and history.
Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21
CFR 1301.33, the above-named company is granted registration as a bulk
manufacturer of Gamma Hydroxybutyric Acid (2010), a basic class of
controlled substance listed in schedule I.
The company plans to manufacture the listed controlled substance
for distribution to its customers.
Dated: August 19, 2014.
Joseph T. Rannazzisi,
Deputy Assistant Administrator.
[FR Doc. 2014-20198 Filed 8-25-14; 8:45 am]
BILLING CODE 4410-09-P
